Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27059448 | 1.00 | HRH3 (0.36) | HRH3MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL16806553 | 0.85 | HRH3 (0.42) | HRH3MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL21865773 | 0.85 | NR1H2 (0.36) | HRH3NR1H2MAPK1BTKCHRM2 | |
| SCHEMBL21801372 | 0.82 | NR1H2 (0.34) | HRH3NR1H2MAPK1BTKCHRM2 | |
| SCHEMBL21801371 | 0.82 | NR1H2 (0.34) | HRH3NR1H2MAPK1BTKCHRM2 | |
| SCHEMBL28885213 | 0.81 | HRH3 (0.33) | HRH3KMT2ANR1H2MAPK1BTK | |
| SCHEMBL30044526 | 0.81 | HRH3 (0.33) | HRH3NR1H2MAPK1 | |
| SCHEMBL28885193 | 0.81 | HRH3 (0.33) | HRH3NR1H2MAPK1 | |
| SCHEMBL28647081 | 0.81 | HRH3 (0.33) | HRH3NR1H2MAPK1 | |
| SCHEMBL30042822 | 0.81 | HRH3 (0.33) | HRH3KMT2ANR1H2MAPK1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590090-B2 | Pyrimidine-and nitrogen-containing bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2026-03-31 | — | — | US | disclosed |
| EP-4223750-B1 | NITROGEN-CONTAINING BICYCLIC COMPOUNDS WHICH CONTAIN PYRIMIDINE AS INTERLEUKIN 1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK-4) INHIBITORS TO BE USED IN THE TREATMENT OF INFLAMMATORY OR AUTOIMMUNE DISEASES | ASAHI KASEI PHARMA CORP (JP) | 2025-06-25 | — | — | EP | disclosed |
| CN-116194454-B | Pyrimidine-containing nitrogen-containing bicyclic compounds | 旭化成制药株式会社 | 2025-02-18 | — | — | CN | disclosed |
| US-20240025893-A1 | PYRIMIDINE-AND NITROGEN-CONTAINING BICYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| EP-4223750-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND WHICH CONTAINS PYRIMIDINE | Asahi Kasei Pharma Corporation (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-4223750-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND WHICH CONTAINS PYRIMIDINE | Asahi Kasei Pharma Corporation (JP) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022070289-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND WHICH CONTAINS PYRIMIDINE | 旭化成ファーマ株式会社 | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025893-A1 | PYRIMIDINE-AND NITROGEN-CONTAINING BICYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | HRH3 1510/4885MEN1 3133/4885ALDH1A1 2898/4885 |
| US-12590090-B2 | Pyrimidine-and nitrogen-containing bicyclic compound | IRAK1, IRAK4, IRAK2 | HRH3 675/4885MEN1 3433/4885ALDH1A1 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.